A St. Louis jury rejected claims that Mead Johnson’s specialized preterm baby formula caused an infant’s dangerous bowel disease. The decision reduces the immediate litigation risk around the product, which may be supportive for Reckitt/Mead Johnson sentiment, though the broader legal exposure remains tied to the overall case docket.
A St. Louis jury rejected claims that Mead Johnson’s specialized preterm baby formula caused an infant’s dangerous bowel disease. The decision reduces the immediate litigation risk around the product, which may be supportive for Reckitt/Mead Johnson sentiment, though the broader legal exposure remains tied to the overall case docket.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
